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Formulation study of dutasteride (BCS class II) and choline alfoscerate
(BCS class III) was conducted to develop film-coated tablets which are 
bioequivalent to commercially available gelatin capsules. Due to the solubility 
issue, commercial soft capsule (Avodart®) was dissolved it in oil phase. In the 
case of choline alfoscerate, it was very hygroscopic and was expected to cause 
diverse tablet processing problems. It was launched as the name of Gliatilin®
soft capsule in which choline alfoscerate was dissolved in glycerin. Generally, 
the physical strength of gelatin shell is known to be weaken in high 
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temperature or can be damaged by external impact such as high pressure. 
Drug contained in soft capsule might leak out of the gelatin shell. To 
overcome the disadvantage of soft capsule, film-coated tablets were 
developed for dutasteride and choline alfoscerate. Cyclodextrin complexation 
technology was applied to enhance the solubility of dutasteride. The 
appropriate solubilizing agents were subsidiarily selected to increase the 
solubility. In vitro dissolution pattern for tablet preparation containing 
dutasteride-cyclodextin complex was shown to be similar to the soft capsules.
AUC value was comparable to Avodart® in the in vivo pharmacokinetic study 
in beagle dogs. The hygroscopicity of choline alfoscerate could be controlled 
by the addition of Neusilin (magnesium aluminometasilicate) in tablet 
preparations. The amount and adding process of Neusilin to tablet were 
examined to confirm the physical stability and rapid disintegration of tablet. 
Choline alfoscerate film-coated tablet with optimized formulation of Neusilin 
was proved to be stable for 3 months under the accelerated condition. In vivo
pharmacokinetic study in healthy Korean male volunteers was performed for 
choline alfoscerate tablet. The mean plasma concentration profile of choline 
was corrected by subtracting the endogenous choline level. The 
bioequivalence between the test tablet and the reference soft capsule of
choline alfoscerate was confirmed. These results suggested that each tablet 
formulations of dutasteride and choline alfoscerate might be substituted for 
the soft capsule.
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1.1. Pros and Cons of soft gelatin capsules
   A soft gelatin capsule is usually consisted of outer gelatin shell and inner 
liquid core with active ingredient. It has developed as an effective 
pharmaceutical dosage form for especially poorly soluble drug and lots of 
them are commercially available. However, there are some advantages and 
disadvantage of soft gelatin capsules as follows [1].
Advantage)
· Improved bioavailability, as the drug is presented as a solubilized form in 
soft gelatin capsule
· Enhanced drug solubility. Protection from light and oxidation for active 
pharmaceutical ingredient (API)
· Consumer preference, masking odors and unpleasant tastes
· Offer opportunities for product differentiation to product line extension
Disadvantage)
· Highly sensitive to heat and humidity, stick together or even break open
· More costly, necessary for the special equipment to fill soft gelatin 
capsule
· Dietary restrictions, animal-free substitute gelatin capsule
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1.2. Selection for solubilization method of dutasteride
Various solubilization technologies for poorly soluble drug are well known 
and applied to drug product. The low solubility of the pooly soluble drug 
often leads to poor bioavailability due to the insufficient exposure of 
dissolved drug portion in the small intestine. A commonly used simple 
technology to improve the solubility of drug is size reduction by milling. And 
also chemical modifications of the compound as salts, cocrystal and 
amorphous are tried for solubilization. Especially solid dispersion with 
polymer using solvent could be considered to enhance the drug solubility but 
it had some issues for physical stability of amorphous drug. It might be 
difficult for the solid dispersion with only small amounts of surfactant to 
expect the dutasteride solubility to increase very high. Emulsion type 
formulation for dutasteride could provide good content uniformity and high 
bioavailability, but it could need large amounts of excipients to adsorb oil 
portion to solid carrier. For this reason, its tablet size would be too large that 
elderly patients might feel difficult to swallow. On the other hand, 
cyclodextrin could solubilize insoluble compound by means of inclusion 
complexation and drug-cyclodextrin aggregates. Cyclodextrin was selected as 
an excipient for solubilization of dutasteride in this paper because it could 
make a function of a good diluent for the solidification process at the same 
time. α-, β-, γ-cyclodextrin were introduced into the GRAS list of the FDA, 
respectively. The water soluble polymer is known to have the inhibitory effect 
on drug nucleation and crystal growth. When cyclodextrin and water soluble 
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polymer were used together, synergic effect was expected on drug 
solubilization. The addition of surfactant could influence on the solubility of 
free drug dissociated with the dilution and degradation of drug-cyclodextrin 
complex in physiological condition. Thus, dutasteride-cyclodextrin complex 
was mixed with water soluble polymer and surfactant to enhance the drug 
solubility.   
1.3. Surface coverage of hygroscopic drug particle by 
Neusilin
Most lubricants are fine powder enough to cover of drug particle surfaces 
with small amounts that they get rid of sticking, picking and even capping 
during tableting process. But over-lubrication of drug with lubricant results in 
weakening bonding between drug particles and causes to significantly reduce 
hardness of tablet. It also leads to the prolongation of disintegration time and 
decrease of the dissolution rate. From this point of view, it is very important to 
select the proper excipient that could efficiently cover the surface of 
hygroscopic drug particle without influencing on disintegration time. And an 
excipient should not negatively effect on the hardness of the tablet to avoid 
any issues during tableting process. Neusilin is a synthetic, amorphous form 
of magnesium aluminometasilicate and used in both direct compression and 
wet granulation as glidant. Neusilin has porous structure to protect sensitive 
API from moisture or adsorb high oily formulation to remain flowable. 
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Neusilin UFL2 is fine powder with submicron diameter and could be used 
more than 30% of tablet weight as excipient. It is expected to effectively 
cover the surface of hygroscopic drug due to its small particle size and high 
contents in tablet. Neusilin was selected as an excipient to understand the 
effect on the moisture stability of choline alfoscerate.
1.4. Pharmacokinetic study for endogenous compound
Particular attention should be paid to the investigation of pharmacokinetics 
of endogenous substance, which could already include the endogenous 
synthesis (homeostatic equilibrium) and supply by dietary route. Baseline 
concentration could be stable or could vary with age, diet, or could have a 
specific rhythm [2]. The correction of pharmacokinetic profile should be 
performed to determine the true concentration added by an exogenous drug 
dosing. Bioequivalence studies of endogenous studies were described in 
EMEA guideline on the investigation of bioequivalence [3].
· If the substance being studied is endogenous, the calculation of 
pharmacokinetic parameters should be performed using baseline 
correction so that the calculated pharmacokinetic parameters refer to the 
additional concentrations provided by the treatment. 
· Factors that may influence the endogenous baseline levels should be 
controlled if possible (e.g. strict control of dietary intake)
· For endogenous substances, the sampling schedule should allow 
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characterisation of the endogenous baseline profile for each subject in 
each period.
· Often, a baseline is determined from 2-3 samples taken before the drug 
products are administered. In other cases, sampling at regular intervals 
throughout 1-2 day(s) prior to administration may be necessary in order 
to account for fluctuations in the endogenous baseline due to circadian 
rhythms.
· The additional concentrations over baseline provided by the treatment 
may be reliably determined.
· The exact method for baseline correction should be pre-specified and 
justified in the study protocol.
· In general, the standard subtractive baseline correction method, meaning 
either subtraction of the mean of individual endogenous pre-dose 
concentrations or subtraction of the individual endogenous predose AUC, 
is preferred.
· In rare cases where substantial increases over baseline endogenous levels 
are seen, baseline correction may not be needed.
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Part I. Formulation of a film-coated dutasteride 
tablet bioequivalent to soft gelatin capsules 




Dutasteride is a competitive inhibitor of type I and type II 5-α-reductases 
and is used to treat benign prostatic hyperplasia (BPH) and hair loss [4]. 
Studies have revealed that dutasteride can reduce fetal adrenal and prostate 
weight and can increase fetal ovarian and testis weight. It has been classified 
as pregnancy category X by the FDA; thus, women who are pregnant or may 
become pregnant must avoid taking and handling dutasteride.
Dutasteride is classified as Biopharmaceutics Classification System (BCS) 
class II and is commercially available in the market only as a soft gelatin 
capsule formulation due to its low aqueous solubility [4]. However, the 
physical strength of the gelatin shell could become weaker under high 
temperature, which might break the seam-line or deform the shape of the 
capsule. Additionally, the active ingredient could migrate into the gelatin shell 
[5]. Because dutasteride is readily absorbed through the skin, these issues can 
lead to various health problems. Therefore, developing a tablet form of 
dutasteride is required to enhance the safety of the drug. Additionally, 
improved patient compliance is expected with a smaller solid tablet than a soft 
gelatin capsule. Moreover, because dutasteride is commonly co-prescribed
with other BPH medicines such as tamsulosin, it would be more convenient to 
formulate solid dosage forms for fixed-dose combinations with other drugs.
Previous studies on solubilization of dutasteride have been mainly focused 
on self-emulsifying drug delivery system (SMEDDS) technology [6-8], which 
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is an oil formulation suitable for soft capsule. To increase the bioavailability 
of various hydrophobic and poorly water-soluble drugs, the drugs can be 
formulated to form a complex with cyclodextrin (CD) as a solid dosage form, 
thereby enhancing their solubility and/or dissolution rate [9-15]. Because no 
covalent bonds are involved in the drug-CD complex formation, the complex 
can be easily dissociated in aqueous solution [16]. Moreover, diverse 
approaches have been attempted to further enhance the complexation efficacy, 
which include the addition of polymers [17], organic salts [18], and buffer [19] 
to the complexation media. Addition of a small amount of a water-soluble 
polymer to an aqueous complexation medium increases the complexation 
efficiency, which consequently can decrease the formulation bulk by reducing 
the amount of CD required [16]. Moreover, water-soluble polymers form 
complexes with various compounds and stabilize micelles and other types of 
aggregates in aqueous solutions [16, 20]. They are additionally capable of 
increasing the aqueous solubility of cyclodextrins without decreasing their 
complexing abilities [21]. Pharmaceutical polymers such as methylcellulose, 
hydroxypropylmethylcellulose and polyvinylpyrrolidone have traditionally 
been used to prevent drug nucleation and crystal growth by creating a 
polymeric network around growing crystals [22]. Thus, their addition leads to 
a decrease in drug crystallization and generates a synergetic effect on the 
solubilizing effect of CDs [11].
Additionally, we assume that the addition of surfactants would further 
enhance the solubilization of free drug dissociated from the drug-CD complex. 
The objective of this study was to investigate the effect of the CD complex on 
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enhancing the aqueous solubility and dissolution of dutasteride, after which 
the formulation was further optimized with diverse polymers and/or 
surfactants. After a film-coated tablet formulation was finalized, its 
pharmacokinetics in beagle dogs was compared to that of Avodart® soft 
capsule.
10
2. Materials and Methods
2.1. Materials
Dutasteride was purchased from Cipla Ltd (Mumbai, India). α-
Cyclodextrin (α-CD), β-Cyclodextrin (β-CD), γ-Cyclodextrin (γ-CD) and 
hydroxypropyl-β-Cyclodextrin (HP-β-CD) were obtained from Wacker 
Chemie AG (München, Germany). Polyvinylpyrrolidone K30 (PVP) (BASF, 
Germany), d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) 
(Isochem, France), stearoyl polyoxylglycerides (Gelucire 50/13) (Gattefosse, 
France), polyethyleneglycol (PEG400) (Yakuri Pure Chem, Japan) and 
polyethyleneoxide-polypropylene oxide copolymer (Poloxamer 407) (BASF, 
Germany) were used as solubilizers. Lactose (SuperTab 11SD) (DFE pharma, 
Japan), microcrystalline cellulose (Avicel PH102) (FMC, USA), crospovidone 
(Polyplasone XL) (Ashland, Netherland), magnesium stearate (Faci, Italy), 
Opadry® (Colorcon, Singapore) and ethylcellulose (Ethocel 10) (Colorcon, 
Korea) were used as excipients for the tablets. Avodart® soft capsules 
(GlaxoSmithKline, United Kingdom) were purchased from a local pharmacy.
2.2. Preparation of dutasteride-cyclodextrin complex and 
solubility study
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Dutasteride-loaded CD complexes were prepared by the oven-drying 
method. Briefly, dutasteride was first dissolved in ethanol at 2 mg/ml 
concentration. Various types of cyclodextrins (α-CD, β-CD, γ-CD, HP-β-CD) 
were separately dissolved in distilled water (DW) at a concentration of 100 
mg/ml. The dutasteride solution and CD solution were homogeneously mixed 
at a 1:1 volume ratio, followed by drying in an oven at 60°C (SANYO, Japan), 
to determine the aqueous solubility of dutasteride complexed with various 
CDs at a 1:50 weight ratio. Dried dutasteride-cyclodextrin (DuCD) complexes 
(equivalent to approximately 0.5 mg of dutasteride) were dispersed in 1.0 ml 
of DW. After gentle stirring for 1 h, undissolved dutasteride was removed 
through filtration (0.45-μm PVDF filter), followed by appropriate dilution 
with a mixture of acetonitrile and water (60/40, v/v). The concentration of 
dutasteride was analyzed using high-performance liquid chromatography 
(HPLC), equipped with a reverse phase C18 column (Zorbax SB-phenyl, 150 x 
3 mm, 3.5 um, Agilent) and UV detector at 240 nm. The mobile phase was a 
mixture of acetonitrile and water (55/45, v/v) at a flow rate of 0.5 ml/min. The 
injection volume was 50 μl [23].
Because the γ-CD complex exhibited the highest solubility among the 
complexes tested, complexes were prepared at various weight ratios 
(1:10~1:70) of dutasteride to γ-CD (DuγCD) to optimize the solubility of 
dutasteride. Next, a 0.4 or 1.0 weight ratio of polymer and/or surfactant was 
added to the dutasteride-γ-Cyclodextrin complex (DuγCD-PS) as a solubility 
auxiliary additive to further enhance the aqueous solubility of dutasteride. The 
aqueous solubility of dutasteride in the DuγCD and DuγCD-PS solutions was 
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determined after filtration as described above. 
2.3. Pharmacokinetics after oral administration of DuγCD-
PS complex in rats
The pharmacokinetics of dutasteride after oral administration of diverse 
DuγCD-PS complexes was compared with that of the reference (Avodart®, 
GlaxoSmithKline) in rats. The animal studies were approved by the WhanIn 
Pharmaceutical Company Animal Ethics Committee. Male Sprague-Dawley 
rats (8 weeks old, 230-270 g) were purchased from DBL Co., Ltd 
(Chungcheongbuk-do, Korea). All rats were habituated for 1 week before the 
experiment and randomly divided into groups of 4~6 animals each. The rats 
were subjected to fasting 12 h prior to the study, and the carotid arteries were 
cannulated with polyethylene tubing PE-50 under isoflurane (I-FRAN 
LIQUID, Hana Pharm Co., Ltd., Seoul, Korea). Each group of animals was 
administered either the reference drug (interior oil content of Avodart® soft 
capsule) or DuγCD-PS complex (suspended in DW) via oral gavage at a dose 
of 2.39 mg/kg of dutasteride, and each rat was orally administered 10 ml/kg of 
DW. Blood samples (approximately 0.3 ml) were collected from the carotid 
artery into heparinized tubes at 0, 0.5, 1, 2, 4, 8, and 24 h after the 
administration. The plasma was obtained by centrifuging the samples at 
13,000 rpm for 5 min and stored at -70°C until analysis.
The concentration of dutasteride in the plasma samples was analyzed 
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using LC/MS/MS, as previously described [24]. Briefly, 100 μl of plasma 
samples was vortex mixed with 900 μL of acetonitrile containing finasteride 
(10 ng/ml) as an internal standard and centrifuged at 13000 rpm. Next, 5 μl of 
supernatant was injected into the LC/MS/MS system. LC separation was 
performed by an Acquity H class UPLC (Waters, USA), and the mass 
spectrometric detection was performed on a TQ Detector (Waters, USA) using 
MRM. A turbo electrospray interface was used in positive ionization mode. 
The major working parameters of LC and the mass spectrometer are 
summarized in Supplement Table S1. The pharmacokinetic parameters (Tmax, 
Cmax, and AUC0-24 h) of dutasteride were analyzed using WinNonlin
® (ver. 6.2, 
Pharsight) based on the linear trapezoidal rule. The relative bioavailability 
(BA) of the DuγCD-PS complexes was calculated as follows:
2.4. Characterization of dutasteride and γ-cyclodextrin 
complexes
The surface morphology was observed using field emission scanning 
electron microscope (FESEM) (JSM-6700F, JEOL, Japan) at an accelerating 
voltage of 5 kV. Samples were spread onto carbon tabs (double-adhesive 
carbon-coated tape) adhered to aluminum stubs, which were then coated with 
a thin layer of platinum. Thermal analysis of DuγCD and DuγCD-PS 
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complexes were conducted by using a differential scanning calorimeter (DSC 
200 F3 Mala, Netzsch). Analyses were performed in an aluminum pan under a 
heating rate of 10°C/min over a temperature range of 20-280°C. XRD Ultima 
III (Rigaku) was used to perform the powder X-ray diffraction (pXRD) 
analyses. The measurement conditions were as follows: scanning speed of 
3°/min and step width of 0.02°. FTIR was observed using Nicolet IR 
Spectrometer (iS50, Thermo, USA).
2.5. Preparation of dutasteride tablet
Tablets of DuγCD-PS complexes (F4 and F5) were prepared by the 
compression method. Briefly, the DuγCD-PS complexes were granulated 
using the fluid-bed granulator (WBF-II, Enger, Taiwan) with a mixture of 
lactose (Super Tab 11SD) and microcrystalline cellulose (Avicel PH 102) as a 
powder bed. The formulation was designed for each tablet (240 mg total 
weight) to contain 0.5 mg of dutasteride. Carr’s index for the granules before 
tablet compression was 18, indicating fair flowability. The granules were 
compressed on a rotary tablet compressor using an 8.5-mm round shape punch, 
and the hardness of the tablet was adjusted between 12 and 13 kp. Next, the 
tablet was film-coated with HPMC-based Opadry®. The dimension of the 
film-coated tablet after 3% weight coating (diameter 8.5 mm, thickness 4.2 
mm, round shape) was smaller compared with the marketed soft gelatin 
capsule Avodart® (length 19 mm, thickness 6.7 mm, rod shape) (Fig. 2).
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2.6. Dissolution test of the dutasteride tablet
In vitro dissolution profiles of dutasteride from the DuγCD-PS complex 
tablet were evaluated by the USP dissolution method (Tier I and Tier II) and 
compared with that of the reference (Avodart®). In the Tier I method, the 
dissolution rates of dutasteride were measured using apparatus 2 in which the 
dissolution medium was 900 ml of 0.1 N HCl solution with 2% (w/v) sodium 
lauryl sulfate (SLS) at 37°C and stirred at 50 rpm. In the Tier II method, the 
dissolution medium was 450 ml of 0.1 N HCl solution with pepsin (1.6 g/L, 
label activity 1:3000) for the first 25 min, followed by the addition of 450 ml 
of 0.1 N HCl solution with SLS (4%, w/v) for the remaining dissolution test. 
The samples (5 ml) were obtained at fixed time intervals and were analyzed 
by HPLC with a UV detector, as described above, after filtering through a 
0.45-µm PVDF filter. 
Additional dissolution test for dutasteride tablet was performed by 
modification of Tier I method. Considering the low surfactant level in 
physiological fluid, the dissolution of F4 and F5 tablets were evaluated in 
various dissolution media containing SLS in the range of 0.1 – 2 w/v%.
2.7. Pharmacokinetic study of the dutasteride tablet in beagle 
dogs
An in vivo cross-over pharmacokinetic study of dutasteride was performed 
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after oral administration of the DuγCD-PS complex tablet or the reference 
(Avodart®) in beagle dogs. The animal studies were approved by the 
Institutional Animal Care and Use Committee of Korea Animal Medical 
Science Institute. Six male beagle dogs (10 kg, 10 months old) were subjected 
to fasting overnight before the experiment. Each dog was administered either 
one capsule of the reference (Avodart®, 0.5 mg as dutasteride) or one tablet of 
DuγCD-PS (F5) (0.5 mg as dutasteride), followed by 10 ml of water. Blood 
samples were taken from the cephalic vein and collected (3 ml) into 
heparinized tubes at 0, 0.5, 1, 2, 4, 8, 12, 24, and 48 h after the administration. 
The plasma was obtained by centrifuging the samples at 3,000 rpm for 5 min 
and stored at -70 °C until analysis. The wash-out period between treatments 
was 4 weeks. The treatment of the plasma samples and the LC/MS/MS 
analysis conditions were the same as that used above for the rat study. The 
Cmax and Tmax were determined from the experimental data. The calculated 
dutasteride concentrations were used to obtain the area under the plasma 
concentration-time profile from time zero to the last concentration time point 
(AUC0-t) by the linear trapezoidal method. Statistical analysis was performed 
with the unpaired t-test where appropriate. Significance was set at p <0.05. 
All data were presented as mean ± standard deviation.
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3. Results
3.1. Effect of cyclodextrin complex on the aqueous solubility 
of dutasteride
Table 1 presents the aqueous solubility of dutasteride when complexed 
with various cyclodextrins at a 1:50 weight ratio, together with their binding 
affinity obtained by the computer docking simulation tool Glide (Schrödinger, 
New York, USA). Among the CDs tested, the γ-CD complex resulted in the 
highest aqueous solubility of dutasteride and showed the lowest binding 
affinity value, indicating stable complex formation. Thus, γ-CD complexes 
with various weight ratios (1:10~1:70) of DuγCD were prepared, and the 
aqueous solubility of dutasteride was determined. The aqueous solubility of 
dutasteride increased up to a 1:70 weight ratio (Table 2), and this value was 
thus selected for further evaluation. It is interesting to note that the solubility 
of dutasteride synergistically increased with the addition of a solubilizing 
polymer at a 0.4 weight ratio (i.e., PVP and PEG) and a surfactant (i.e., 
Gelucire, TPGS and Poloxamer) to the DuγCD complex (dutasteride : γ-
Cyclodextrin = 1:70) (Table 3). The highest solubility of dutasteride achieved 
with the addition of the 0.4 weight ratio of PVP and Gelucire was 147 μg/ml, 
which is 1.5 times higher than the solubility of DuγCD (1:70) (93 μg/ml). In a 
previous report, the highest solubility of dutasteride was only 47.1 μg/ml 
when dutasteride was complexed with HP-β-CD and HPMC at a weight ratio 
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of 1:26.6:13.3 [25]. Moreover, the study prepared the complex by the 
supercritical fluid manufacturing method, which is environmentally friendly 
but not widely equipped in pharmaceutical companies. Thus, it is notable that 
DuγCD-PS prepared by the simple drying method achieved an aqueous 
solubility of dutasteride that was higher than the reported solubility.
Based on the preliminary solubility study, DuγCD-PS complexes were 
further optimized by changing the weight ratio of dutasteride to γ-CD (1:10 to 
1:70) and surfactant. Table 4 presents the composition of DuγCD-PS 
complexes selected for further evaluation and the aqueous solubility of 
dutasteride. When the 0.4 weight ratio of PVP was selected as a solubilizing 
polymer, the solubility of dutasteride increased up to 170 μg/ml as the content 
of the surfactant (Gelucire:TPGS=1:1) increased to 2 weight ratio (F5). These 
results are consistent with previous reports that the addition of a water-soluble 
polymer synergistically enhances the solubilizing effect of CDs by preventing 
drug nucleation and/or crystal growth [11]. Moreover, it is notable that the 
surfactant further increased the solubility of dutasteride, which supports our 
assumption that surfactants would further enhance the drug solubility by 
solubilizing the free drug dissociated from the drug-CD complex.
3.2. Pharmacokinetic study of DuγCD-PS complex in rats
The plasma concentration profiles of dutasteride after oral administration 
of Avodart® or the DuγCD-PS complex at a dose of 2.39 mg/kg of dutasteride 
in rats are presented in Fig. 3, and the pharmacokinetic parameters are 
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summarized in Table 5. DuγCD-PS complexes (F1) with 10 and 0.4 weight 
ratios of γCD and surfactant, respectively, resulted in only 29.6% relative BA 
compared to that of the reference (Avodart®). However, when the weight ratio 
of γCD increased to 30 and 50 (F2 and F3, respectively), the relative BA of 
dutasteride increased up to 74% of the reference. Moreover, the addition of 
surfactant at a weight ratio of 2 (F4 and F5) further increased the relative BA 
up to 93.6% of the reference. To understand the effect of solubilization by 
DuγCD-PS complexes on oral absorption in rat, the correlation solubility with 
AUC0-t in rat was plotted (r
2 = 9763, Fig. 4)
For BCS class II drugs including dutasteride, improving the aqueous 
solubility is the most practical strategy to increase its oral bioavailability by 
enhancing the dissolution of the drug in the gastrointestinal (GI) tract [26]. As 
the solubility of dutasteride increased by increasing the drug to γ-CD weight 
ratio and by adding surfactant (Table 4), the relative BA of dutasteride 
increased proportionally (Table 5). In addition to the solubilizing effect of γ-
CD, surfactant appears to synergistically enhance the bioavailability (F3 vs. 
F4) by inhibiting precipitation and solubilizing the free drug dissociated from 
the CD complex, as we assumed. However, it is interesting to note that the 
increase in the γ-CD weight ratio up to 70 (F5) could not further increase the 
relative BA of dutasteride, despite its higher solubility than F4 formulation. It 
is known that γ-CD solubilizes poorly water-soluble drugs by inclusion of 
insoluble drug into its hydrophobic cavity and formation of γ-CD aggregates 
[18]. However, the drug could additionally be embedded among γ-CD 
aggregates at a high CD ratio, resulting in supersaturation of the drug. The 
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drug is easily released by the dissociation of γ-CD aggregates (by dilution in 
the gastrointestinal fluid and/or by the ring opening of γ-CD with the attack of 
digestive enzyme), after which the drug may be precipitated. Surfactant might 
not be able to sufficiently inhibit the precipitation of supersaturated 
dutasteride in F5 in vivo; thus, the higher solubility of dutasteride compared to 
F4 could not proportionally increase the bioavailability. 
3.3. Characterization of dutasteride and γ-cyclodextrin 
complexes
Surface morphology of dutasteride observed by the FESEM was irregular 
in shape, while γCD was a parallelogram shape. However, the morphology of 
complexes was similar to an aggregate (Fig. 5). In FTIR study, characteristic 
peaks of dutasteride in the range of 1650-1700 cm-1 (carbonyl stretching), 
1600 cm-1 (N-H bend) were markedly decreased in γ-CD complexes (Fig. 6).
DSC and pXRD are useful techniques to determine the occurrence of 
inclusion of drug crystals. The thermograms of dutasteride and the complexes 
are presented in Fig. 7(A). Dutasteride showed a very sharp endothermic peak 
at 251°C, which corresponds to its melting temperature. It is notable that the 
endothermic peak of dutasteride was almost negligible when the weight ratio 
of γCD was higher than 1:30 in the DuγCD complexes. Moreover, as shown 
in Fig. 7(B), the endothermic peak of dutasteride completely disappeared in 
DuγCD-PS complexes (F3, F4 and F5) containing solubilizing polymer (i.e., 
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PVP) and surfactant (i.e., Gelucire and TPGS), indicating that dutasteride is 
present in an amorphous form in DuγCD-PS complexes. Moreover, the pXRD 
results of the DuγCD-PS complexes were consistent with those of DSC and 
did not exhibit the specific pattern for dutasteride crystal (Fig. 8). Because 
both F4 and F5 formulations could achieve high bioavailability (93.6%) 
compared to the reference, they were selected for preparing the tablet 
formulation.
3.4. Dissolution study of DuγCD-PS tablet
Fig. 9 presents the in vitro dissolution profiles of dutasteride from the
tablets of DuγCD-PS complexes (F4 and F5) coated with HPMC-based 
Opadry®, which were compared with that of the reference (Avodart®, soft 
gelatin capsule). In the Tier I method (Fig. 9A), dissolution of F5 was more 
rapid than that of F4 and the reference for the first 15 min. However, both F4 
and F5 tablets showed a complete release of dutasteride within 45 min, which 
is similar to the reference. Notably, dutasteride was not dissolved for the first 
25 min until SLS was added in the Tier II method (Fig. 9B), indicating the 
importance of surfactants in the release medium to mimic the physiological 
condition. Moreover, it was previously reported that poorly water-soluble 
drugs can be solubilized in the gastrointestinal tract by endogenous surfactants 
including bile acids, bile salts and lecithin [27].
Considering the low surfactant level in physiological fluid, the dissolution 
profiles of F4 and F5 tablets were shown in Fig 10. F4 tablet with a relatively 
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low solubility showed a low dissolution rate at 15min in 0.7w/v% SLS 
containing dissolution media. Whereas F5 tablet showed rapid dissolution rate 
at 10 min regardless of the concentration of SLS in media (0.1-2w/v %) as 
well as the reference. The DuγCD-PS complex (1:70:0.4:2) used in F5 tablet 
contained higher amounts of γ-cyclodextrin than that(1:50:0.4:2) in F4 tablet. 
High solubility of F5 tablet was seemed to maintain a high dissolution rate 
even though a small amount of SLS was contained in dissolution media. 
Dutasteride is classified as a BCS class II drug, which implies that it is 
highly membrane permeable and lipophilic with a log P value of 5.09. Its 
terminal elimination half-life is known to be very long (3-5 weeks) at steady-
state in humans [24]. Thus, rapid initial dissolution of dutasteride from the 
tablet followed by gastrointestinal absorption would be critical to achieve a 
similar pharmacokinetic profile after oral administration. Based on the in vitro
dissolution study, the F5 tablet was selected for the in vivo animal study.
3.5. Pharmacokinetic study of DuγCD-PS tablet in beagle 
dogs
Fig. 11 shows the plasma concentration profiles of dutasteride after oral 
administration of Avodart® or the tablet of DuγCD-PS complexes (F5) in 
beagle dogs. Their pharmacokinetic parameters summarized in Table 6 
indicate that the Cmax and AUC0-t values were not significantly different. P-
values were greater than 0.05 when T-test was applied to the pharmacokinetic 
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data. Notably, the Tmax value of F5 was shorter than that of the reference, 
which is consistent with the in vitro dissolution study (Fig. 7). Moreover, the 
relative bioavailability of F5 was 92.4% of that of the reference. Thus, further 
investigation would be necessary with a larger number of animals and/or 




The present study provided the development possibility of dutasteride 
tablet. Mono-dosing of dutasteride was only 0.5mg per tablet but its water 
solubility was very low. To prepare the solid dosage form, cyclodextrin was 
selected as a proper main solubilizer due to the ease of powdering and the 
increase of drug solubility by the interaction drug molecule and hydrophobic 
interior cavity of CD. The γ-cyclodextrin was determined as the suitable 
cyclodextrin by drug solubility test and computer docking simulation for 
complexation. The inclusion complex formation depended on the chemical 
structures and physicochemical properties of both guest and CD molecules
[28]. Dutasteride had a larger aromatic ring like the steroidal structure, which 
seemed to be easier to pose into γ-cyclodextrin with larger cavity size. It 
coincided to the results of the lowest binding energy in computer simulation 
and the highest drug solubility to γ-cyclodextrin among CDs (Table 1). In the 
preparation of DuγCD complex by the change of the weight ratio (1:10~1:70), 
the higher the ratio of γ-cyclodextrin was, the higher the solubility of the drug
was (Table 2). Maybe, cyclodextrin was presumed to solubilize dutasteride by 
making drug-cyclodextrin solid dispersion/aggregate in addition to inclusion 
complexation. Additionally, polyvinylpyrrolidone and gelucire/TPGS added 
to DuγCD complex were shown to act as solubility adjuvant to increase the 
drug solubility (Table 3). F4 and F5 composition(Drug : γ-CD : polymer : 
surfactant = 1:50:0.4:2, 1:70:0.4:2, respectively) exhibited comparatively high
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solubility of drug. Their solubilities were 118.9ug/mL, 170.6ug/mL
respectively (Table 4), which were markedly higher in comparison with that 
of HP-β-CD complex for dutasteride in the previous study, 47.1ug/mL [25]. 
The crystallinity of drug was proved to disappear after preparation of 
cyclodextrin complex, considering from the data of DSC and pXRD (Fig. 7–
Fig. 8). To confirm the level of solubilization by CD complex, in vivo oral 
absorption study in rat was tested compared with the soft capsule. To 
understand the IVIVC of DuγCD-PS complex, the correlation between in 
vitro solubility data and in vivo AUC0-t in rat was plotted(r
2 = 0.9763, Fig. 4). 
The absorption rate of dutasteride increased by the increase of the drug 
solubility, which was consistent with the fact that dutasteride was a BCS class 
II drug. As a result, the complex with solubility more than about 120ug/mL 
was expected to be bioequivalent to the reference drug in rat. 
The fluid-bed granulation method was applied as the solidification 
process for DuγCD-PS complex. The flowability of final mixture was fair and 
any issues for tableting and coating process were not occurred. It was judged
to manufacture the dutasteride tablets commercially through the check for the 
preparation unit process and inter process control for granules. 8.5mm round 
type core tablets using DuγCD-PS complexes (F4 and F5) were prepared with 
a weight of 240mg. Dutasteride tablet was expected to enhance the patient 
compliance compared with the Avodart® soft capsule of 18mm length (Fig. 2).
The dissolution for dutasteride tablet was performed whether 
enhancement of drug solubilization by cyclodextrin and solubility adjuvants 
properly effected on drug release from tablet. The dissolution conditions 
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followed the dissolution method for soft capsule of dutasteride listed on US 
FDA site. The both F4 and F5 tablets showed the equivalent dissolution 
profiles to soft capsule under Tier I and Tier II dissolution conditions (Fig. 9). 
In aspect that complete dissolution was observed in dutasteride tablet within 
45min in dissolution media, solubilization of dutasteride by DuγCD-PS 
complex was estimated to be effective. According to Tier II method, 
dissolution was performed in 450mL of 0.1N HCl solution with pepsin for the 
first 25min, followed by the addition of 450mL of 0.1N HCl solution with 
4w/v% SLS for the remaining dissolution test. Tier II method was guessed to 
show the effect of SLS on gelatin capsule shell because SLS was well known 
protein solubilizer and denaturant and might retard the dissolution of drug 
from gelatin capsule [29]. So, The Tier II condition was seemed to be suitable 
to evaluate the dissolution for gelatin capsule. For that reason, the dissolution 
of dutasteride tablet was carried out according to Tier I method in which SLS 
was already added in the beginning of dissolution. The F5 composition with 
higher solubility than F4 was selected as a candidate for pharmacokinetic 
study in beagle dogs. Prior to animal testing, Tier I dissolution condition was 
carefully reviewed for the test tablet and also partially modified to get the 
meaningful correlation between in vitro dissolution and in vivo PK profile, 
considering of low surfactant level in physiological fluid. SLS could 
accelerate dissolution rate and extent of poorly soluble drug by the increase of 
wetting through reduction of the interfacial tension and micellar solubilization 
of drug. Low level of surfactants in dissolution medium recommended to give 
a better correlation between in vitro and in vivo data [30]. In the case of F4 
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tablet, the concentration of SLS in dissolution media was affected to the 
dissolution rate of dutasteride. The dissolution profile for F4 was low 
compared with that of reference tablet in dissolution media with low level of 
SLS (0.7 w/v %). On the other hand, F5 tablet showed the similar dissolution 
profiles regardless of SLS contents(0.1~2 w/v %) in dissolution media. With 
this result, F5 tablet was administered into beagle dogs. Its pharmacokinetic 
parameters, Cmax and AUC0-t values were not significantly different from those 
of reference when statistical analysis was performed with the t-test (P>0.05). 
T-test analysis was performed between the two groups because the number of 
six animals was not enough for statistical analysis using ANOVA. Tmax value 
of F5 was shorter than that of the reference, which is consistent with the in 
vitro dissolution study. The relative bioavailability of F5 tablet was 92.4% 
compared with soft capsule and judged to be bioequivalent to soft capsule in 
beagle dog. But further investigation would be necessary with a larger number 
of animals to prove clearly the bioequivalence of F5 tablet to soft capsule. 
And also, additional formulation study might be needed for more
solubilization of drug to pass the bioequivalence in human because the human 
GI tract is longer than beagle dog, considering the oral absorption difference 
between rat and beagle dog.
Thus, it could be confirmed that the formulation strategy of introducing 
the concept of cyclodextrin complex was working for solubility enhancement 
of dutasteride. The manufacturing process was established using fluid bed 
granulator and considered to apply successfully for commercial production. 
Finally, dutasteride tablet was expected to avoid safety issues for children and 
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women by percutaneous absorption because there was not worried about the
leakage of solubilized drug by the damage of gelatin shell. And dutasteride 




DuγCD-PS complexes were successfully prepared by the simple oven-
drying method. The amorphous form of dutasteride was confirmed via DSC 
and pXRD studies. In vitro dissolution of dutasteride from the tablets of 
DuγCD-PS complexes was comparable with that from the reference (Avodart®, 
soft gelatin capsule). Moreover, in vivo pharmacokinetic parameters of the 
DuγCD-PS complex tablet after oral administration in beagle dogs were not 
significantly different from that of the reference. These results suggest the 
feasibility of developing a tablet formulation of dutasteride with 
bioequivalence to the commercial soft gelatin capsule, which requires further 
evaluation in a larger number of animals and/or humans.
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Table 1 Aqueous solubility of dutasteride complexed with various 
cyclodextrins at a 1:50 weight ratio and the average binding affinity as 










*Each value is the mean ± SD (n=3).
ND: not determined.
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Table 2 Effect of the weight ratio of dutasteride:γ-cyclodextrin (DuγCD) on 








*Each value is the mean ± SD (n=3).
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Table 3 Effect of the solubilizing polymer and surfactant on the aqueous 
solubility of dutasteride (μg/ml) added to the DuγCD (1:70) complex at 
weight ratios of 0.4 and 1.0, respectively. 
*Each value is the mean ± SD (n=3).





















Dutasteride γ- CD Polymer a Surfactant
F1 1 10 0.4 0.4b 33.8±1.5
F2 1 30 0.4 0.4 b 97.3±3.1
F3 1 50 0.4 0.4 b 104.5±3.0
F4 1 50 0.4 2 c 118.9±3.4




*Each value is the mean ± SD (n=3).
34
Table 5 Pharmacokinetic parameters of dutasteride after oral administration of 
















10.4 ± 7.8 253.4 ± 22.8 4336.9 ± 497.4 -
F1 12.0 ± 8.0 63.7 ± 23.5 1282.4 ± 334.9 29.6
F2 8.9 ± 9.0 148.8 ± 31.9 3147.3 ± 689.1 72.6
F3 10.4 ± 7.8 170.6 ± 43.4 3228.2 ± 459.9 74.4
F4 3.0 ± 1.2 215.2 ± 51.3 4061.1 ± 588.9 93.6
F5 11.0 ± 8.9 195.8 ± 21.3 4060.2 ± 295.3 93.6
Each value is the mean ± SD (n=4~6).
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Table 6 Pharmacokinetic parameters of the reference or F5 tablet after oral 













Reference 1.7 ± 0.5 67.3 ± 17.9 1964.7 ± 546.1 -
F5 1.2 ± 0.7 61.2 ± 16.9 1815.6 ± 532.4 92.4
P-value N/A 0.5990 0.5593 -
N/A : Not assessed
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Table S1 Working parameters of LC and the tandem mass spectrometer for 
analysis of dutasteride in the plasma. 
Parameter Value
< LC system>
Column ACQUITY UPLC® BEH C18 (2.1 x 50 mm, 1.7 µm)
Column Mobile 
Phase
Solvent A: 100% water with 0.1% formic acid
Solvent B: 100% acetonitrile with 0.1% formic acid










Flow rate 0.4 ml/min




TQ Detector (Waters, USA)
Ion source ES+
Temperatures Source Temp: 120 °C, Desolvation Temp: 350 °C















Dutasteride 529.33 461.27 0.161 62 35
Finasteride 373.2 305.17 0.161 56 28
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Figure 1 Chemical structure of dutasteride
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Figure 2 Comparison of the size of Avodart® soft gelatin capsule (left) and the 
dutasteride tablet (right).
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Figure 3 Mean plasma concentration-time profiles of dutasteride after oral 
administration of the DuγCD-PS complex at a dose of 2.39 mg/kg of 
dutasteride in rats (n=4~6). Each point and vertical bar represent the mean and 
standard deviation, respectively.
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Figure 4 Correlation between the solubility of DuγCD-PS complexes(F1-F5) 




























Figure 5 Scanning electron microscope of (A) dutasteride (X5000), (B) γ-
cyclodextrin (X1000), (C) DuγCD complex (1:70) (X1000), and (D) DuγCD-
PS complex (1:70:0.4:2, F5) (X1000).
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Figure 6 FTIR Spectra of (A) dutasteride, (B) γ-cyclodextrin, (C) DuγCD 












Figure 7 DSC thermograms of the (A) DuγCD complexes and (B) DuγCD-PS 
complexes.
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Figure 8 Powder X-ray diffraction pattern of the DuγCD-PS complexes.
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Figure 9 In vitro dissolution profiles of dutasteride from the reference soft 
gelatin capsule (Avodart®) and the film-coated tablets of DuγCD-PS 
complexes determined following the USP dissolution method (A) Tier I and 










































































Figure 10 In vitro dissolution profiles of dutasteride from (A) the reference 
soft gelatin capsule (Avodart®), (B) the film-coated tablet (F4), and (C) the 
film-coated tablet (F5) in dissolution media with the various SLS contents 
(Tier I modified). 
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Figure 11 Mean plasma concentration-time profiles of dutasteride after oral 
administration of the reference soft gelatin capsule (Avodart®) or the F5 tablet 
in beagle dogs (n=6, crossover). Each point and vertical bar represent the 
mean and standard deviation, respectively.
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Part II. Formulation of a film-coated choline 
alfoscerate tablet bioequivalent to soft gelatin 
capsules (Gliatilin®): Effect of Neusilin
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1. Introduction
Choline alfoscerate (Fig. 1) is hydrolyzed to choline which is the precursor 
for the neurotransmitter acetylcholine, and is used for the improvement of 
cognitive dysfunction in dementia of neurodegenerative and vascular origin 
[31, 32]. It has an elimination half-life of 0.5~6.2 hr [33] and is completely 
absorbed following oral administration [34]. Choline alfoscerate is 
commercially available as soft capsule and administered 400 mg each three 
times a day. The physical strength of the gelatin shell could become weaker 
under high temperature and the gelatin shell can deform at high temperature. 
The drug dissolved in soft gelatin can also migrate to the gelatin shell over 
time [35]. Thus, a tablet dosage form of choline alfoscerate was developed to 
overcome these disadvantages of soft capsule. Unfortunately, however, 
choline alfoscerate is highly hygroscopic, and thus choline alfoscerate powder 
is apt to turn to be sticky when it is exposed to humid air during 
manufacturing process. This could be the main reason that the first 
commercial preparation (Gliatilin®, Reference) of choline alfoscerate was 
launched in the market as a soft capsule, in which choline alfoscerate was 
dissolved in glycerin. Formulation strategy of developing a choline alfoscerate 
tablet in this study was to select suitable excipients that could efficiently 
surround the surface of the drug to inhibit the water absorption. However, the 
amount of hydrophobic excipients needed to be minimized since they could 
retard the dissolution [36], thereby negatively influencing the result of the 
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bioequivalence of tablet. Based on the formulation studies, magnesium 
aluminosilicate (Neusilin) was selected as a proper excipient, and tablet 
formulation was designed to include minimum amount of Neusilin.
Choline alfoscerate is readily hydrolyzed by phosphodiesterases in the gut 
mucosa to form free choline [37]. The active major metabolite, choline can be 
measured in plasma following oral administration of choline alfoscerate and 
the increased plasma levels of choline reflects the absorption of choline 
alfoscerate [34]. Choline in plasma can be measured using liquid 
chromatography with tandem mass spectrometry (LC/MS/MS). However, 
choline is an endogenous material which comes from one of two sources, the 
dietary intake and synthesis by de novo pathway from phosphatidylcholine et 
al [38]. The difference level of endogenous choline concentrations may cause 
subject variability in drug absorption and failure in bioequivalence studies. 
Thus, the absorption of choline by drug administration should be checked 
under choline-limited diet control of healthy volunteers and the removal of 
individual interference by endogenous choline. 
The aim of the present study was to investigate the optimum tablet 
formulation of choline alfoscerate and to compare the bioequivalence between 
a newly formulated tablet (Alfocetine®, test drug) and soft capsule(Gliatilin®, 
reference drug) according to the KFDA guidelines [39] in healthy Korean 
male volunteers. The absorbed plasma concentration of choline after drug 
administration was determined, and was calculated by correcting with the 
baseline values determined before dosing at the same plasma sampling time [3, 
39].
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2. Materials and Methods
2.1. Materials
Choline alfoscerate was purchased from HanseoChem (Kyeonggi-do, 
Republic of Korea). Magnesium aluminometasilicate (Neusilin, Fuji Chemical, 
Japan) was used to control the water absorption of drug and to improve the 
granule fluidity. Polyvinylpyrrolidone K30 (PVP) (BASF, Germany) was 
added as binder. Microcrystalline cellulose (Mingtai chemical, Taiwan), 
lactose monohydrate and lactose anhydrous (DFE Pharma, Germany) and 
dicalcium phosphate anhydrous(DCP A-TAB, Innophos, USA) were used as 
excipients for the tablets. Croscarmellose sodium(DFE Pharma, Japan), 
Sodium starch glycolate (Yung zip, Taiwan), crospovidone (Polyplasdone XL, 
Ashland, Netherland), magnesium stearate(Faci, Italy) and sodium stearyl 
fumarate (Pruv, JRS Pharma, Spain) were tested as superdisintegrant and 
lubricant, respectively. Opadry I® and Opadry AMB® were obtained from 
Colorcon(Shanghai, China). Gliatilin® soft capsules (Daewoong 
Pharmaceutical, Seoul, Republic of Korea) were purchased from a local 
pharmacy.
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2.2. Selection of excipient to block the water absorption of 
drug
Choline alfoscerate was a powder form with a little good flowability. But 
it was highly hygroscopic and was apt to be sticky under the exposure to the 
air. It caused sticking and picking problem during tablet manufacturing 
process, in which choline alfoscerate adhered to the surface of a tablet-punch 
face. The commonly used excipients for tablet were listed as Table 1 and 
tested for their ability to prevent water uptake of choline alfoscerate. 1g of 
choline alfoscerate was mixed with each excipient at the same weight and 
relative moisture uptake (%) was calculated by comparing the weight gain 
before and after left in an 80% RH condition for 1day. The excipients with 
relatively low moisture uptake were selected for the tablet formulation of 
choline alfoscerate.
2.3. Formulation study of choline alfoscerate tablet 
Wet granulation method was applied in preparing the choline alfoscerate 
tablet. Table 2 shows the composition of core tablets to observe the effect of 
Neusilin on the protection of moisture uptake and disintegration time. 
Neusilin (5%-30%) was added both in and out of the granules in order to 
surround the drug particles more efficiently [40]. Briefly, after preblending 
choline alfoscerate with Neusilin and microcrystalline cellulose, the 
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granulation process was performed using high speed mixer 
(PharmaConnectTM, GEA, Germany) with 70% ethanol binder solution 
containing PVP K-30. The binder solution was sprayed through a 0.3 mm 
spray nozzle at 1.5 bar, followed by drying at 50℃ in the oven (MOV-212S, 
Sanyo, Japan). Then, the granules were mixed with Neusilin, dicalcium 
phosphate, and croscarmellose sodium. After adding lubricant (sodium stearyl 
fumarate), oblong-shaped core tablets were compressed using the tableting 
machine (Rimek MINI II SF, Karnavati Engineering, India). Tablet processing 
problems including sticking, picking, laminating and punch-filling issue for 
each composition were recorded. 
The core tablets were subcoated with HPMC based Opadry I® using 
organic solvent for 1% weight gain and followed by coating with PVA based 
Opadry AMB® using aqueous system for 3% weight gain to improve the water 
stability during storage of tablet [40]. 
2.4. Effect of Neusilin on the water stability and the 
disintegration time of tablet
2.4.1. Moisture uptake of core tablet
Weight gain by moisture uptake was measured to evaluate the effect of 
Neusilin at various contents (F1-F4, Table 2) and ratios of inter/intragranules
(F5-F8, Table 2). Core tablets were put in the petri dish and left for 1 day in 
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the desiccator with 80% RH, equilibrium with the saturated aqueous solution 
of ammonium sulfate [41]. The weight gain(%) was determined by measuring 
the weight of tablets before and after storage in desiccator. 
2.4.2. Disintegration time of core tablet
Disintegration time for core tablets was determined in water using 
disintegrator (DIT-200, Fine Scientific, Republic of Korea) by the 
disintegration method, USP. Soft capsule was also tested for disintegration as 
control.
2.4.3. Appearance change of film coated tablet
To evaluate the water stability for film coated tablet under various RH 
conditions, the desiccators with 22%, 33%, 60% and 80% RH were prepared 
using different saturated salts solution with potassium acetate, magnesium 
chloride, sodium bromide and ammonium sulfate, respectively [41]. Film-
coated tablet containing of 15% Neusilin with 1:2 ratio of inter/intragranules 
was tested for the appearance stability. Film coated tablet was put on petri 
dishes as open state in desiccators for up to 30days. The time point at which 
the appearance began to change due to the uptake of moisture was recorded. 
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2.5. In vitro evaluation of test drug and reference drug
2.5.1. Test drug and Reference drug
Test drug (Alfocetine® tablet) was manufactured with Neusilin at a 
suitable ratio in Whanin Pharmaceutical company. Based on the formulation 
study of choline alfoscerate tablet, less than 18% of Neusilin to tablet weight 
was used. Not less than 50% of this was added into granules and the residual 
Neusilin was mixed with choline alfoscerate granules. And reference drug 
(Gliatilin® soft capsule) was produced by Daewoong Pharmaceutical company.
2.5.2. In vitro dissolution test
The dissolution of choline alfoscerate was measured using USP apparatus 
2 (paddle). The dissolution medium was 900 mL of distilled water at 37 ± 
0.5°C and stirred at 50 rpm. Dissolution study was conducted on 12 individual
film coated test tablets or reference soft capsules. At the predetermined 
intervals (0, 5, 10, 15 and 30 min), 5 mL of the medium was sampled and 
filtered through a membrane filter (0.45 μm). Then, the concentration of 
choline alfoscerate was analyzed by using the high-performance liquid 
chromatography (HPLC) system with refractive index (RI) detector (Waters 
410, Waters, MA, USA) [42]. Zorbax SB-CN column (250 x 4.6 mm, 5um, 
Agilent) filled with porous silica particles chemically bonded with nitrile 
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groups was applied for analytical assay and maintained at 38℃. The mobile 
phase was a mixture of acetonitrile and water (60/40, v/v) at a flow rate of 1.5 
ml/min. The injection volume was 20 µL.
2.5.3. Stability test in the accelerated condition
Stability of the film coated tablets packaged with Zymax blister film 
(Bilcare, Singapore) was tested after keeping in the accelerated chamber (40℃
/75% RH) for 3months (Table 3). Appearance, assay and disintegration were 
compared with those of the reference soft capsule. The content of choline 
alfoscerate was analyzed by HPLC system, as described above. Hardness of 
test tablet was also checked using the hardness tester (MT50, Sotax, 
Switzerland), which is apt to be lowered by the moisture uptake. Dissolution 
test in water was also performed for the test tablets.
2.6. Bioequivalence study
2.6.1. Subjects
The bioequivalence study was conducted at Yangji Hospital (Seoul,
Republic of Korea) with 19-46 aged healthy Korean male volunteers. All 
subjects were determined to be in good health based on medical history, 
physical examination and hematological examination. Subjects were excluded 
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if they had hypersensitivity to any ingredient in the choline alfoscerate tablets, 
took other drugs that could interfere with the study results within 10 days 
before this trial, had taken alcohol or medications that induce or inhibit drug-
metabolizing enzymes (ex. barbitals) within 1 month before this study. All 
subjects signed a written informed consent after explained the purpose, the 
methods and the adverse drug reactions of this study in accordance with the 
regulatory guideline [39]. Subjects were monitored by hospital staff during 
the study period using interview, vital sign measurement, adverse event 
collection and physical examination. 
2.6.2. Study design
This study was performed under fasted conditions with a randomized, 
single-dose, 2-period crossover design [39]. All subjects randomized in this 
crossover study received a single dose of choline alfoscerate of test tablet and 
reference soft capsule, separated by 7 days of washout between treatments.
The protocol was approved by the Yangji Hospital institutional review board
(IRB). Subjects were hospitalized for 5 days before the study and exercise, 
meal, smoking and consumption of grapefruit juice were restricted from 10hr 
before the beginning of the trial to the end of blood collecting. During the trial, 
consumption of food and drink, except water, were controlled and choline-
free meals were provided. 
Subjects were fasted for 10 hours before and 4 hours after drug 
administration to exclude the effects of diet. Two groups were treated with 
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1200 mg (choline alfoscerate 400 mg x 3 doses) of the reference capsule or 
the test tablet orally with 150 mL of water at 8 A.M. Subjects were not 
allowed to drink water for 1 hour before and after drug administration. 
Choline restricted standard meals were provided for lunch and dinner at 4 and 
10 hours after dosing. After the Period I blood collection, subjects returned 
home and were advised to avoid excessive drinking, taking drugs, drinking 
grapefruit and to prohibit excessive intake of choline-containing foods (e.g., 
eggs, beans). After 7 days for washout period, all subjects were called up to 
hospitalize for 5 days before the study and administered in the same manner 
as in the Period I.
A total of 24 blood samples were collected at predetermined time points (0, 
0.5, 0.75, 1, 1.33, 1.67, 2, 3, 4, 6, 8 and 12 hours) on one day before drug 
dosing and on the day of drug administration. Before collecting each blood 
sample, 1 mL of blood was drawn and discarded to completely remove any 
remaining saline in the catheter. Aliquot (8 mL) of blood was collected into 
vaccutainer with sodium heparin and then 1 mL of heparinized normal saline 
was injected into the catheter to prevent blood clotting. Blood samples were 
centrifuged at 3,000 rpm for 10 minutes. The plasma was transferred to 
Eppendorf tube and stored at -70°C until analysis.
2.6.3. Determination of plasma choline concentrations
Choline concentration in each plasma sample was determined by a 
validated liquid chromatography-tandem mass spectrometry (LC-MS-MS) 
59
assay for choline [43]. The plasma samples were placed at room temperature 
to thaw. Aliquot (1 mL) of metformin (20 ng/mL in methanol) was added as 
internal standard (IS) to 50 μL of plasma. Each sample was vortexed and
centrifuged at 12,000 rpm for 5 min. The supernatant (2 μL) of the mixture 
was taken and chromatically analyzed by Shiseido Nanospace SI-2 (Osaka 
Soda, Japan) with an Luna 3μm HILIC (3 μm, 2.0 mm I.D.´150 mm L., 
Phenomenex, CA, USA). The mobile phase consisted of 1 mM ammonium 
formate and acetonitrile (45 : 55, v/v%). The flow rate was 0.3 mL/min. 
Column and sample tray temperatures were set at 45°C and 4°C, respectively. 
Detection and quantification were measured by Triple Quadruple Mass 
Spectrometer System, API 4000 (AB SCIEX, Canada) in positive ion 
electrospray ionization (ESI+) with the multiple reaction monitoring (MRM) 
mode. The m/z value of the precursor to product for choline and IS were 
104.2 → 60.1 and 113.3 → 69.1, respectively. The LC-MS-MS system was 
controlled by using Analyst software (version 1.4, AB SCIEX, Canada) and 
the results were processed by using Microsoft Office Excel 2007 (Microsoft 
Corp., Washington, USA). The validation of this chromatographic analytical 
method was performed in order to evaluate its specificity, linearity, precision, 
accuracy and stability in solution. The calibration curve from the standard 
choline samples was constructed based on the peak area measurements, which 
was linear in 0.05 -10 μg/mL range.
2.6.4. Pharmacokinetic and statistical analysis
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The concentration of choline in the plasma before and after drug 
administration was calculated with the peak area ratio of choline to the 
internal standard, metformin. The choline concentration after drug absorption 
at each time point was calculated by subtracting the endogenous choline level 
of the same blood collection point of each subject before the drug 
administration. When negative value was obtained after correction, it was 
considered as zero [44].
The pharmacokinetic parameters of choline were determined for both test 
tablet and reference soft capsule using a noncompartmental model with BA 
Calc 2007 program (version 1.0.0., MFDS, Seoul, Korea) [45]. The Cmax and 
Tmax were determined from the experimental data. The elimination rate 
constant (ke) was calculated from the least-squares regression slope of the 
terminal plasma concentration, and then the t1/2 value was calculated as 
0.693/ke. The calculated choline plasma concentrations were used to obtain 
the area under the plasma concentration-time profile from time zero to the last 
concentration time point (AUC0-t). The AUC0-12 was calculated by the linear 
trapezoidal method [46]. AUC0–∞ was calculated as AUC0–12 + C12/ke, where 
C12 was the choline concentration at the last time point (12 hr). Comparative 
bioavailability was measured by 90% confidence intervals (CIs) of the 
geometric mean ratios of test to reference which were determined using log-
transformed data of AUC0–t and Cmax. All statistical calculations were 
performed using K-BE Test 2007 program (version 1.1.0., MFDS, Seoul, 
Korea) for bioequivalence analysis program recommended by the MFDS [47]. 
The KFDA regulatory range of bioequivalence for 90% CIs of geometric 
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mean ratios is 0.8-1.25 [39].
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3. Results
3.1. Effect of Neusilin on the moisture uptake and the 
disintegration time of tablet
3.1.1. Moisture uptake and disintegration time of core tablet
Proper excipients with low moisture uptake rates were selected by 
category for the formulation of choline alfoscerate tablet. Table 1 summarized 
the list of excipients tested for the formulation of choline alfoscerate tablets 
and the weight gain (%) due to moisture uptake when each mixture was left in 
80% RH condition for 1 day. Choline alfoscerate powder had good flowability, 
but was highly hygroscopic and was apt to be sticky under the exposure to air. 
It would cause sticking and picking problem during tablet manufacturing 
process by adhering to the surface of a tablet-punch face. When each excipient 
was mixed with choline alfoscerate, the amount of moisture uptake decreased 
because the surface area of drug exposed to the air decreased. Based on the 
moisture uptake measurement, the excipients with low moisture uptake were 
selected and marked in Table 1. It was notable that Neusilin showed lowest 
moisture uptake among tested. It is known to have ultrafine particle size of 
15nm and high porosity [48]. Large surface area of Neusilin was expected to 
improve the stability of the drug against moisture by surrounding it with a 
small amount, thereby minimizing the retardation effect on the dissolution 
63
rate.
Core tablets containing Neusilin with various contents and ratios of 
inter/intragranules were evaluated in terms of the tablet processing problems 
(Table 2). As shown in Table 2, the average weight of core tablets was in the 
range of 530~780 mg depending on the compositions and the hardness of the 
tablets was maintained in the range of 18~20 kp. F1 composition containing 5% 
Neusilin showed sticking and picking phenomenon during tableting process 
due to the insufficient amounts of it. Although higher content (30%) of 
Neusilin (F4) did not cause the tablet processing problem, the disintegration 
of tablet was retarded up to 19 min. Since the disintegration time of the 
reference soft capsule was 10 min, 15% Neusilin was selected, and was added 
in and out of granules at various ratio (F5~F8). When Neusilin was added 
only in granules (F5), sticking and picking were observed during the tableting 
process and weight gain by moisture uptake was relatively high. Moreover, 
when Neusilin was added out of the granules only (F8), filling of final mixture 
into the punch was not smooth enough. Thus, F7 composition was selected for 
film coating since the disintegration time was less than 10 min without tablet 
processing problem and the lowest moisture uptake. Neusilin was not added 
into intergranules but also was placed between granules. These core tablets 
were shown the similar disintegration time to reference drug without any 
tablet process problems. The proper distribution of Neusilin to 
inter/intragranules was needed to efficiently enclose the drug. 
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3.1.2. Appearance stability of film coated tablet
Fig. 2 shows the time point when the appearance of tablet began to change 
due to the uptake of moisture at various RH conditions. When the tablets took 
moisture, the film coating layer was broken by the swelling of core or water 
droplets were formed on the surface of tablets. It was noteworthy that the 
film-coated tablet of F7 maintained the appearance for up to 30 days in 60% 
RH condition. 
3.2. In vitro evaluation of test drug and reference drug
3.2.1. In vitro dissolution test
Fig. 3 shows the dissolution profiles of choline alfoscerate (400 mg) from 
the film-coated test tablet and the reference soft capsules in distilled water. It 
was notable that the dissolution rate of choline alfoscerate from the test tablet 
was higher than that of the reference soft capsule for 10 min. It was probably 
due to the slower disintegration of gelatin shell than that of the tablet, and also 
indicated that Neusilin in tablet formulation did not affect the dissolution of 
choline alfoscerate. Moreover, the average dissolution rate of both test and 
reference reached not less than 85% within 15 minutes and dissolution 
profiles were accepted as similar, according to the KFDA guidelines [39]. In 
soft capsules, the deviation of dissolution was bigger than the test tablet, 
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which was seemed to be caused by the individual difference of disintegration 
of gelatin shell.
3.2.2. Stability test in the accelerated condition
The stability of the film-coated test tablet and the reference soft capsule 
stored under the accelerated condition for 3 months was summarized in Table 
3. There was no change in appearance, disintegration time, content and 
harness of the test tablet during the storage period. Moreover, the dissolution 
profiles of choline alfoscerate in water were within the acceptance level of 
similarity with the initial for 3 months (Fig. 4). Based on the results of the 
stability studies under the accelerated condition, it was concluded that the 
hygroscopicity of choline alfoscerate was effectively controlled in the film-
coated tablet, and thus the bioequivalence between the tablet and the soft 
capsule was tested in human. 
3.3. Bioequivalence study
3.3.1. Subjects
Age 19-46 years old (mean ± SD: 27.7±6.5), height 158-188 cm (mean ±
SD: 173.3 ± 6.6), weight 55-96 kg (mean ± SD: 69.4 ± 8.3) of fifty healthy 
Korean male volunteers were enrolled in this study. All of the subjects 
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completed the study in period 1, but 2 subjects withdrew in period 2. One 
subject withdrew because of acute upper respiratory infections, and the other 
subject withdrew because of a bruised leg. Thus, 48 subjects completed the 
study and were included in the pharmacokinetic analysis.
3.3.2. Pharmacokinetic analysis
Figure 5 showed the mean plasma concentration profiles of choline before 
and after the administration of test tablet and reference soft capsule. The 
corrected plasma concentration-time curve by subtracting the endogenous 
choline level was shown in the Figure 6, which suggested that test tablet had
similar bioavailability to the reference soft capsule. The major mean 
pharmacokinetic parameters such as AUC0-t, Cmax and Tmax for two 
preparations were summarized in Table 4. The mean AUC0-∞ for the test tablet 
was 3.43 ± 2.17 μg×h/mL and was not significantly different from that of the 
reference soft capsule (3.31 ± 1.80 μg×h/mL). The mean Cmax of test tablet 
(0.37 ± 0.16 μg/mL) was also not significantly different from that of the 
reference soft capsule (0.38 ± 0.11 μg/mL). The mean Tmax of test tablet and 
reference soft capsule were 3.51 ± 2.57 and 3.85 ± 3.19 hours, respectively, 
and was not significantly different, although the initial dissolution rate of 
choline alfoscerate from the reference soft capsule was slightly slower than 
that from the test tablet (Figure 3).
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3.3.3. Statistical analysis and bioequivalence evaluation
Statistical results of bioequivalence evaluation between two formulations 
of choline alfoscerate 400 mg in healthy Korean male volunteers were 
summarized in Table 5. The calculated 90% confidence intervals (CIs) for 
geometric mean ratios of test to reference of AUC0–t and Cmax were 0.8451-
1.1198 and 0.8331-1.0410, respectively, and were satisfied with the accepted 
bioequivalence criterial of 0.80-1.25. Moreover, AUC0–t and Cmax of the test 
tablet (Alfocetine®) and the reference soft capsule (Gliatilin®) were not 
significantly different.
3.3.4. Tolerability
Tolerability was recorded by vital sign, adverse event and physical 
examination, and no adverse events were reported during this study. Two 
subjects were excluded from the trial because of an acute upper respiratory 
tract infection (runny nose, cough) and a bruised leg with external impact 
during washout period and later fully recovered. These findings were 
considered to have little causal relationship with the drug.
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4. Discussion
In this study, the formulation strategy was proposed on the development 
of tablet dosage form for choline alfoscerate. The functional excipients were 
screened to prevent the hygroscopicity of drug. Drug was changed to be wet 
and eventually liquefied within only 1day under 80% RH. Neusilin was 
selected as a proper excipient to minimize the hygroscopic property of drug
because it showed the lowest moisture uptake among various excipients
(Table 1). Small amounts of Neusilin could efficiently cover the surface of 
drug to block the moisture absorption because it had wide surface area and 
high porosity. A formulation design was required to use small amounts of 
effective excipient because choline alfoscerate was a drug for elderly person 
and tablet size should be minimized for patient compliance. Under this 
viewpoint, formulation strategies as follows were introduced in developing 
the choline alfoscerate tablet, 1) choline alfoscerate was granulated to reduce
surface area of drug exposed to the air; 2) Neusilin was added into choline 
alfoscerate granules to control hygroscopicity of drug; 3) choline alfoscerate-
containing granules were surrounded with Neusilin by simply mixing process 
to minimize the drug exposure; 4) After tableting, core tablet was subcoated 
with HPMC using organic solvent and followed by coating with water-
dispersible moisture barrier coating system(Opadry AMB). Prototype 
compositions were prepared in the range of 5% - 30% Neusilin and more than 
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14% Neusilin could be solved for tablet processing problem due to the 
hygroscopicity of drug. When Neusilin was applied only into granules or 
outer granules, it could cause the tableting issues like as sticking or picking 
due to the insufficient coverage of drug (Table 2). As a result, it was necessary 
to add Neusilin into intergruanules and intragranules at the proper ratio of 2:1-
1:2 to make tablet without any problems during tableting process. The 
moisture stability for F7 film coated tablet was tested as open state in various 
RH conditions (Fig. 2). Appearance stability of F7 tablet in 60% RH had been
kept for about 1 month. This meant that choline alfoscerate tablet could be 
circulated in the market for a month without the change of appearance as 
packaged with medicinal porridge in drugstore, considering the annual 
average relative humidity in Seoul was 64%. The F7 tablet was packaged with 
PVDC blister (packaging type for commercialization) and stored at the 
accelerated condition(40℃/75% RH) for 3 months. There was no change in 
appearance and hardness during storage period for test tablet (Table 3). From 
this result, it was turned out that the hygroscopicity of drug might be 
effectively controlled using Neusilin in film coated tablet. 
The bioequivalence study for choline alfoscerate tablet was designed 
according to the regulatory guideline for endogenous compound. Because 
choline alfoscerate was hydrolyzed into choline, endogenous substance, oral 
absorption by drug dosing should be corrected by the baseline of choline. 
Before drug dosing, endogenous baseline profile was checked for each subject 
who was managed to have choline restricted standard meal. The in vivo oral 
pharmacokinetic parameter of choline alfoscerate tablet was compared to 
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reference soft capsule. Statistical results of bioequivalence evaluation in 
healthy Korean male volunteers (Table 5) showed that AUC0-t and Cmax were 
not significantly different between test tablet and reference soft capsule and 
satisfied with the acceptance criteria of 0.80-1.25. 
Thus, we could confirm that choline alfoscerate tablet was prepared by 
controlling the contents and inter/intragranular ratio of Neusilin without any 
tableting issue. The stability data in accelerated condition revealed that 
choline alfoscerate tablet was stable in appearance and dissolution for 3 
months. The result of in vivo pharmacokinetic study suggested that tablet
formulation containing Neusilin prepared in this study indicated bioequivalent 
to soft capsule for choline alfoscerate. 
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5. Conclusion
The hygroscopicity of choline alfoscerate was effectively controlled by 
using Neusilin in the preparation of film coated tablet. The proper content of 
Neusilin and its inter/intragranular distribution in tablet allowed to 
disintegrate of tablet quickly and led to eliminate the tablet process problems. 
The stability of tablet under the accelerated condition proved that film coated 
tablet of choline alfoscerate was successfully prepared. In the bioequivalence 
test of healthy Korean male volunteers, no significant differences in 
pharmacokinetic parameters were found between the test tablet and the 
reference soft capsule since 90% confidence intervals for AUC0-t and Cmax
were within the regulatory acceptance criteria. These results indicated that the 
new tablet formulation (Alfocetine®) can be prescribed as an alternative to 
choline alfoscerate soft capsule. 
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Drug Choline alfoscerate only 18.7±0.4a
Diluent
Dicalcium phosphate 28.2±1.0 √




Polyvinylpyrrolidone K-30 31.8±1.2 √
Hydroxypropylcellulose 32.8±1.6
Superdisintegrant
Croscarmellose sodium 33.4±1.0 √









Sodium stearyl fumarate 29.0±1.4 √
* Weight gain (%) to choline alfoscerate (1g) when each mixture was left at 80% 
RH for 1 day. 
a Weight gain (%) to choline alfoscerate powder (1g), which changed to be 
wet and eventually liquefied.
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Table 2. Compositions of the Choline alfoscerate core tablets and effect of 
Neusilin on tablet processing problems and disintegration of tablet
Compositions F1 F2 F3 F4 F5 F6 F7 F8
Choline alfoscerate
(mg)



















DCP/MCC(%) 11 17 17 10 15 15 15 15
PVP K-30(%) 2 2 0.5 1 0.5 0.5 0.5 0.9
Croscarmellose 
Na(%)
5 5 5 5 5 5 5 5
Sodium Stearyl 
Fumarate(%)
2 2 2 2 2 2 2 2






































13 11 11 19 13 10 9 8
a Weight percent to total tablet weight
b Weight increase rate(%) to core tablets when it was left as open state at 80% 
RH for 1day
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Table 3. Stability for test drug and reference drug of choline alfoscerate 
400mg after 3 months storage under the accelerated condition (40℃/75% RH).
Test Reference









Assay a 100.1±1.3% 101.9±0.4% 99.9±1.0% 101.2±1.2%
Disintegration, 
water 
9 min 9 min 10 min 12 min
Hardness a 21.0±0.8 kp 20.7±1.2 kp - -
a Values were expressed as mean ± standard deviation. 
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Table 4. Pharmacokinetic parameters of choline after single oral 
administration of choline alfoscerate 1200 mg (n=48).
Parametera Test Reference
AUC0-t (μg∙h/mL) 2.01±0.77 2.00±0.84
AUC0-∞ (μg∙h/mL) 3.43±2.17 3.31±1.80
Cmax (μg/mL) 0.37±0.16 0.38±0.11
Tmax (h) 3.51±2.57 3.85±3.19
t1/2 (h) 6.82±6.80 5.25±3.80
a Values were expressed as mean ± standard deviation except median 
(ranges) for Tmax.
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Table 5. Statistical results of bioequivalence evaluation between test drug and 























a Values were log-transformed.
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Figure 1. The structure of choline alfoscerate (L-Alpha glycerylphosphoryl
choline).
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Figure 2. Appearance stability of choline alfoscerate film coated tablet 
containing 15% Neusilin with 1:2 ratio of inter/intragranules when left as 


































Figure 3. In vitro dissolution test for test drug and reference drug of choline 























Figure 4. Dissolution profiles of choline alfoscerate from the film coated 
























(A)   
(B)
Figure 5. Baseline-uncorrected mean plasma concentration-time curve of 
choline (A) after oral administration of test tablet (Alfocetine®) or reference 
soft capsule (Gliatilin®) at the dose of choline alfoscerate 1200 mg, and (B) 
before drug administration. Vertical bars represent the standard deviation 
(n=48). 
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Figure 6. Baseline- corrected mean plasma concentration-time curve of 
choline after oral administration of test tablet (Alfocetine®) or reference soft 
capsule (Gliatilin®) at the dose of choline alfoscerate 1200 mg. The choline 
concentration after drug administration at each time point was calculated by 
subtracting the endogenous choline level of the same blood collection point of 
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국문초록
본 연구에서는 상업적으로 생산되고 있는 연질캡슐제제와
동등수준의 정제 제형을 개발하기 위해 서로 다른 물성을 보이는
2 종의 주성분을 대상으로 하여 제제화전략을 수립하였고 in 
vivo 에서의 생체동등성을 확인하였다. 일반적으로 연질캡슐의 경우
고온에서 젤라틴 피막의 성상 변화가 일어나거나 장기간 보관시
내부에 용해되어 있던 약물이 젤라틴 피막으로 이행되는 경우가
있다. 고온 및 외부 충격에 의한 젤라틴피막의 물리적 강도의
약화는 피막의 손상으로 이루어져 내부에 봉입되어 있는 약물이
누출되는 문제점이 있다. 약물의 용해도 이슈로 인해 연질캡슐제로
개발된 두타스테라이드와 약물의 수분안정성 이유로 연질캡슐제로
시판된 콜린알포세레이트, 두 약물에 대해 각각 가용화연구와
인습방지연구를 진행하여 연질캡슐과 동등수준의 품질기준을
만족하는 필름코팅정을 제조하였다. 각 정제는 대조약인 연질캡슐제
대비 동등한 in vitro 용출패턴을 나타냄을 확인하였다. BCS class 
II 약물인 두타스테라이드의 경우 감마사이클로덱스트린과의
포접연구 및 적절한 용해보조제를 선택함으로써 원하는 용출패턴을
얻을 수 있었다. BCS class III 약물인 콜린알포세레이트의 경우
주성분의 함습을 방지하기 위해 노이실린(메타규산알루민산
마그네슘)을 과립내외에 적절한 비율로 첨가함으로써 타정장애 없이
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안정한 필름코팅정을 제조할 수 있었다. 두타스테라이드정은
대조약인 아보다트연질캡슐보다 작은 크기로 개발되어 노인 환자의
복약편의성을 증진시킬 수 있을 것으로 예상되었으며 연질캡슐과
달리 주성분이 고형상태로 제형화되었기 때문에 연질캡슐과는 달리
약물 누출에 따른 안전성 이슈를 해결할 것으로 기대된다. 
두타스테라이드정은 비글견을 이용한 약물동태시험을 통해
연질캡슐과 in vivo 에서의 동등성을 확인하였다. 
콜린알포세레이트정은 가속조건에서 3 개월간 안정함을
확인하였으며 건강한 성인남자를 대상으로한 생체동등성 평가에서
연질캡슐과의 동등성을 입증하였다.
주요어 : 정제; 연질캡슐제; 두타스테라이드; 콜린알포세레이트; 
생체동등성
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